These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 7912423

  • 1. Primary chemotherapy in epithelial ovarian cancer.
    Hurwitz HI, McGuire WP.
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):141-54. PubMed ID: 7912423
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [Abstract] [Full Text] [Related]

  • 3. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Oct; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 4. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [Abstract] [Full Text] [Related]

  • 5. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
    Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS.
    J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
    [Abstract] [Full Text] [Related]

  • 6. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY, Barnes MN, Niwas S, Robertson MW, Alvarez R, Austin JM, Kilgore LC, Partridge EE.
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [Abstract] [Full Text] [Related]

  • 11. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
    Orr JW, Orr P, Kern DH.
    Cancer J Sci Am; 1999 Feb; 5(3):174-8. PubMed ID: 10367175
    [Abstract] [Full Text] [Related]

  • 12. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F.
    Oncology; 2009 Feb; 76(1):49-54. PubMed ID: 19039248
    [Abstract] [Full Text] [Related]

  • 13. Advances in the management of epithelial ovarian cancer.
    Berkenblit A, Cannistra SA.
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [Abstract] [Full Text] [Related]

  • 14. Retrospective study of the prognostic factors of remission induction for single-agent chemotherapy with cisplatin in advanced epithelial ovarian cancer.
    Matsumoto Y, Deguchi M, Ishiko O, Ogita S.
    Oncol Rep; 2000 Jun; 7(2):311-3. PubMed ID: 10671677
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 16. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S, EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm.
    J Natl Cancer Inst; 2003 Jan 15; 95(2):113-25. PubMed ID: 12529344
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Feasibility of intraperitoneal chemotherapy in advanced epithelial ovarian cancer.
    Maheshwari A, Gupta S, Prabhash K, Tongaonkar HB.
    Indian J Cancer; 2010 Jan 15; 47(2):225-6. PubMed ID: 20448394
    [No Abstract] [Full Text] [Related]

  • 19. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY, Zhang R, Huang MN, Li N, Wang GX, Liu LY.
    Ai Zheng; 2003 Apr 15; 22(4):424-7. PubMed ID: 12704005
    [Abstract] [Full Text] [Related]

  • 20. Effect of progesterone combined with chemotherapy on epithelial ovarian cancer.
    Chen X, Feng Y.
    Chin Med J (Engl); 2003 Mar 15; 116(3):388-91. PubMed ID: 12781043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.